Filing Details
- Accession Number:
- 0000899243-21-009196
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-03-02 21:00:32
- Reporting Period:
- 2021-02-26
- Accepted Time:
- 2021-03-02 21:00:32
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1655759 | Arvinas Inc. | ARVN | Pharmaceutical Preparations (2834) | 472566120 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1753537 | G John Houston | C/O Arvinas, Inc. 5 Science Park, 395 Winchester Ave. New Haven CT 06511 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-06-30 | 315 | $28.50 | 817,938 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2020-12-31 | 310 | $29.02 | 818,248 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2021-03-02 | 17,510 | $0.00 | 835,758 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-03-02 | 8,115 | $77.45 | 827,643 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | A | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Acquisiton | 2021-02-26 | 219,500 | $0.00 | 219,500 | $78.30 |
| Common Stock | Restricted Stock Units | Disposition | 2021-03-02 | 17,510 | $0.00 | 17,510 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2031-02-25 | No | 4 | A | Direct | |
| 35,021 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 817,623 | Direct |
Footnotes
- On March 23, 2020, the reporting person filed a Form 4 that incorrectly disclosed the sale of shares of common stock to cover withholding taxes following the vesting of previously granted Restricted Stock Units. The correct number of shares sold was 5,542, not 5,405, reducing the number of securities beneficially owned by the reporting person by 137 shares.
- The shares were acquired under the 2018 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- Includes 315 shares acquired under the 2018 Employee Stock Purchase Plan.
- Includes an aggregate of 625 shares acquired under the 2018 Employee Stock Purchase Plan.
- Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock.
- This sale was made to cover withholding taxes following the vesting of previously granted Restricted Stock Units.
- The broker sold shares of the Issuer's common stock for certain employees following the vesting of previously granted Restricted Stock Units, including the common stock reported on this Form 4 by the reporting person, at an average price of $77.4495.
- This option award was granted on February 26, 2021. 1/4 of the shares underlying the award shall vest on February 26, 2022, with the remainder of the shares vesting in equal monthly installments following February 26, 2022 through February 26, 2025.
- On March 1, 2019, the reporting person was granted 70,042 Restricted Stock Units, vesting in four equal annual installments beginning March 1, 2020.
Billionaire Hedge Funds
